Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2007 (First Quarter of Fiscal Year 2008)
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, along with related disposables and information services. The company operates as a single segment with product families serving blood donors, patients, and software/services.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 FY2008 (Ended June 30, 2007) |
Q1 FY2007 (Ended July 1, 2006) |
|---|---|---|
| Net Revenues | $121,936 | $110,674 |
| Gross Profit | $61,494 | $57,373 |
| Gross Margin | 50.4% | 51.8% |
| Operating Income | $15,779 | $14,891 |
| Operating Margin | 12.9% | 13.5% |
| Net Income | $12,677 | $11,156 |
| Diluted EPS | $0.46 | $0.40 |
| Cash and Cash Equivalents | $216,056 | $260,031 |
| Working Capital | $316,951 | $321,654 |
| Total Debt (Current + Long-term) | $25,123 | $28,876 |
| Net Cash Provided by Operating Activities | $14,181 | $17,509 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10.2% year-over-year, driven by a 6.4% increase in disposables, a 55.7% surge in software and services, and a 24.3% rise in equipment sales. Foreign exchange rates had a slight negative impact of 0.2% on total revenue.
- Profitability: Net income rose 13.6% to $12.7 million. Operating income increased 6.0%. However, gross margin compressed to 50.4% from 51.8% due to product mix shifts toward lower-margin commercial plasma products and consulting services.
- Foreign Exchange Impact: A stronger U.S. dollar negatively impacted results. Without FX effects, operating income would have increased 26.6% and net income 38.0%.
- Operating Expenses: Total operating expenses increased 7.6%. Research and Development (R&D) rose 15.8% due to expenses from recent acquisitions (Arryx and IDM). Selling, General, and Administrative (SG&A) increased 6.9%, largely due to $1.4 million in ERP implementation costs.
- Cash Flow: Operating cash flow decreased $3.3 million to $14.2 million, primarily due to a $6.4 million increase in inventory (driven by plasma market demand) and changes in working capital. Financing activities used $18.5 million, primarily for $24.8 million in share repurchases.
Guidance, Outlook, and Risks
- Restructuring: Management approved a plan to consolidate European customer support functions in Signy, Switzerland. The company expects to incur $4 million to $5 million in exit costs, with $1.4 million recorded in the current quarter. This is expected to yield annual operating savings of approximately $1.5 million.
- Acquisitions: On July 9, 2007 (subsequent to period end), the company acquired Infonalé, Inc. for approximately $1.3 million in cash plus contingent consideration to optimize hospital blood use management.
- Tax Rate: The effective tax rate was 31.2% for the quarter, compared to 35.6% in the prior year, aided by a $0.5 million discrete benefit from the expiration of a statute of limitations in Japan. The company expects an annual tax rate of approximately 34.25% for the remainder of fiscal 2008.
- Share Repurchases: The company repurchased 0.6 million shares for $29.5 million during the quarter. As of June 30, 2007, $45.5 million remained available under the $75.0 million Board-approved limit.
- Risks: Key risks include foreign currency fluctuations (hedged via forward contracts), regulatory uncertainties, competitive pricing, and the impact of industry consolidation in the plasma market.
Investor Verification Checklist
- Inventory Build: Verify the sustainability of the $6.4 million increase in inventory and its impact on future working capital needs.
- FX Hedging Effectiveness: Review the composite index hedge spot rates and the company's exposure to the Euro and Japanese Yen given the significant negative impact of currency on the quarter's results.
- Restructuring Costs: Monitor the execution of the European consolidation plan and the realization of the projected $1.5 million in annual savings.
- Software Growth: Assess the organic growth component of the 55.7% increase in software revenue versus the contribution from the IDM acquisition.
- Share Repurchase Program: Track the remaining $45.5 million authorization and the company's commitment to returning capital to shareholders.